CliffBio
small molecule

WAINUA

EPLONTERSEN SODIUM

Loss of exclusivityAugust 2034latest FDA-listed patent expiry
CompanyASTRAZENECA AB

Drug detail

Brand nameWAINUA
Active ingredientEPLONTERSEN SODIUM
StrengthEQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalApril 2026
Marketing statusRX

Listed patents

PatentExpiresType
10683499August 2034substance, product
9181549May 2034substance
9127276May 2034substance

More from ASTRAZENECA AB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

WAINUA patent cliff — loss of exclusivity August 2034 | CliffBio